Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Status of Application, Amendments, and/or Claims
1. Claims 1-35 are pending and currently under consideration.
Information Disclosure Statement
2. The information disclosure statement filed on 08/11/2026, 04/21/2026, 02/11/2026, 09/26/2025, 03/07/2025, 01/03/2025, 12/12/2024, and 09/19/2024 has been considered by the Examiner and an initialed copy of the form PTO-1449 is attached to this communication.
Drawings
3. The drawing filed on 05/24/2024 are accepted by the examiner.
Claim Rejections[Symbol font/0xBE] Nonstatutory Obviousness-Type Double Patenting
4. Basis for nonstatutory double patenting:
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission.
For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/ guidance/eTD-info-I.jsp.
5. Claims 25-30 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-30 of US Patent No. 12,030,938 B2. Although the conflicting claims are not identical, they are not patentably distinct from each other for the following reasons.
Claims 1-30 of US Patent No. 12,030,938 B2 are drawn to a method of treating a GPC3-expressing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a recombinant polynucleic acid encapsulated by a nanoparticle delivery vehicle, wherein the recombinant polynucleic acid comprises a sequence encoding a chimeric fusion protein (CFP), the CFP comprising: (a) an extracellular domain comprising an anti-GPC3 binding domain, wherein the extracellular domain further comprises an extracellular domain or fragment thereof from CD16a, CD64, CD68 or CD89, and (b) a transmembrane domain operatively linked to the extracellular domain, wherein the transmembrane domain comprises a transmembrane domain from CD16a, CD64, CD68 or CD89; wherein the CFP is expressed on the surface of myeloid cells of the subject that express endogenous FcR-gamma receptors; wherein the anti-GPC3 binding domain comprises: (i) a heavy chain comprising a heavy chain variable domain, the heavy chain variable domain comprising a heavy chain complementarity determining region 1 (HC CDR1) sequence of DYEMH (amino acid residues 31-35 of SEQ ID NO: 97), a HC CDR2 sequence of ALDPKTGDTAYSQKFKG (amino acid residues 50-66 of SEQ ID NO: 97) and a HC CDR3 (HC CDR3) sequence of FYSYTY (amino acid residues 99-104 of SEQ ID NO: 97); and (ii) a light chain comprising a light chain variable domain comprising: a light chain complementarity determining region 1 (LC CDR1) sequence of RSSQSLVHSNRNTYLH (amino acid residues 24-39 of SEQ ID NO: 98), a LC CDR2 sequence of KVSNRFS (amino acid residues 55-61 of SEQ ID NO: 98) and a LC CDR3 sequence of SQNTHVPPT (amino acid residues 94-102 of SEQ ID NO: 98).
Claims 25-30 of the instant application are drawn to the same method except that the polynucleic acid sequence encoding a chimeric fusion protein (CFP) is an mRNA. Claims 1-30 of US Patent No. 12,030,938 B2 and claims 25-30 of the instant application vary in scope and are obvious over each other.
Claim Rejections[Symbol font/0xBE]35 USC § 102 (a)(2)
6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
7. Claims 21-22 and 24 are rejected under 35 U.S.C. 102 (a)(2) as being anticipated by US 12,698,340 B2 (Date of Patent: Aug. 4, 2026; earliest filing date: Oct. 1, 2018).
US 12,698,340 B2 teaches a δ1 γδ T cell comprising a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises (i) a binding domain that specifically binds to GPC3; (ii) a CD8α hinge domain; (iii) a CD8α transmembrane domain; (iv) a costimulatory signaling region selected from a 4-1BB costimulatory signaling region and a CD27 costimulatory signaling region; and (v) a CD3ζ C. signaling domain: or b. a polypeptide comprising a CAR comprising an amino acid sequence encoded by the nucleic acid of (a); wherein the δ1 γδ T cell functionally expresses the binding domain of the polypeptide or the nucleic acid encoded CAR on the surface of the δ1 γδ T cell, and wherein the nucleic acid encodes SEQ ID NO: 20, which is 98.3% identical to the amino acid sequence of SEQ ID NO: 106 of the instant application, comprises the six CDRs recited in claim 21 of the instant application, and comprises a heavy chain variable domain comprising an amino acid sequence that is 98.8% identical to the amino acid sequence of SEQ ID NO: 97 and a light chain variable domain comprising an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 98 of the instant application (see sequence alignment below). Thus, the teachings of US 12,698,340 B2 meet the limitations of claims 21-22 and 24.
PNG
media_image1.png
906
796
media_image1.png
Greyscale
Claim Objection
8. Claim 23 is objected to because it depends on a rejected claim.
Conclusion
9. Claims 1-20 and 31-35 are allowed, claims 21-22, 24, and 25-30 are rejected, claim 23 is objected.
Advisory Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vanessa Ford, can be reached on (571) 272-0857. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.
/RUIXIANG LI/Primary Examiner, Art Unit 1674
October 16, 2026